PapersFlow Research Brief
Ubiquitin and proteasome pathways
Research Guide
What is Ubiquitin and proteasome pathways?
The ubiquitin and proteasome pathways constitute a selective proteolytic system in eukaryotic cells where short-lived proteins are targeted for degradation through covalent attachment of ubiquitin, followed by proteasomal breakdown.
This field encompasses 76,032 papers on mechanisms of protein degradation via the ubiquitin-proteasome system, including regulation by E3 ubiquitin ligases and deubiquitinating enzymes. Key processes involve polyubiquitin chain formation and roles of SUMOylation in modulating pathway activity. The system regulates critical cellular functions such as NF-κB activation and serves as a target for proteasome inhibitors in cancer therapy.
Topic Hierarchy
Research Sub-Topics
E3 Ubiquitin Ligase Regulation
This sub-topic investigates substrate specificity, activation mechanisms, and scaffolding functions of E3 ligases in protein turnover. Studies link dysregulation to diseases like cancer and neurodegeneration.
Deubiquitinating Enzymes Mechanisms
Research elucidates DUB catalytic domains, chain editing, and roles in signaling reversal across ubiquitin topologies. High-throughput screening identifies inhibitors for therapeutic modulation.
Proteasome Inhibitors in Cancer Therapy
Developments in bortezomib-like inhibitors target 20S/26S subunits, overcoming resistance via combination therapies. Clinical trials assess efficacy in hematologic and solid tumors.
Ubiquitin Polyubiquitin Chain Topologies
This area maps linkage-specific chains (K48, K63, etc.) decoded by receptors for degradation vs. signaling pathways. Mass spec and structural biology reveal signal diversity.
Ubiquitin Proteasome in NF-κB Activation
Mechanisms of non-degradative ubiquitination in IκB kinase signaling and pathway crosstalk are dissected using knockout models. Implications for inflammation and oncogenesis are explored.
Why It Matters
The ubiquitin-proteasome pathway controls degradation of regulatory proteins, impacting cell cycle progression and disease states. Hershko and Ciechanover (1998) in "THE UBIQUITIN SYSTEM" detailed how ubiquitin ligation targets short-lived proteins, a mechanism central to processes like p53-mediated growth control as described by Levine (1997) in "p53, the Cellular Gatekeeper for Growth and Division", which has garnered 7663 citations. Proteasome inhibitors exploit this pathway for cancer therapy, addressing protein homeostasis in tumors, while dysregulation contributes to conditions involving NF-κB activation.
Reading Guide
Where to Start
"THE UBIQUITIN SYSTEM" by Hershko and Ciechanover (1998) provides the foundational explanation of ubiquitin-mediated protein targeting and degradation, making it the ideal starting point for understanding core mechanisms.
Key Papers Explained
Hershko and Ciechanover (1998) in "THE UBIQUITIN SYSTEM" establishes the ubiquitin conjugation cascade, which underpins regulatory protein turnover detailed in Levine (1997) "p53, the Cellular Gatekeeper for Growth and Division" where p53 stability relies on ubiquitination, and Sherr and Roberts (1999) "CDK inhibitors: positive and negative regulators of G1-phase progression" link CDK inhibitor degradation to cell cycle control via this pathway. Weinberg (1995) in "The retinoblastoma protein and cell cycle control" extends this to Rb protein regulation. These works collectively trace ubiquitin's role from basic ligation to cell cycle checkpoints.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current research emphasizes regulation of E3 ubiquitin ligases and deubiquitinating enzymes, alongside SUMOylation effects and proteasome inhibitors for cancer therapy. Exploration continues into polyubiquitin chain topologies and NF-κB pathway integration, with the field comprising 76,032 works.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | THE UBIQUITIN SYSTEM | 1998 | Annual Review of Bioch... | 8.7K | ✕ |
| 2 | A novel gene containing a trinucleotide repeat that is expande... | 1993 | Cell | 8.3K | ✓ |
| 3 | p53, the Cellular Gatekeeper for Growth and Division | 1997 | Cell | 7.7K | ✓ |
| 4 | LC3, a mammalian homologue of yeast Apg8p, is localized in aut... | 2000 | The EMBO Journal | 6.5K | ✓ |
| 5 | CDK inhibitors: positive and negative regulators of G1-phase p... | 1999 | Genes & Development | 6.1K | ✓ |
| 6 | Molecular mechanisms and clinical applications of angiogenesis | 2011 | Nature | 5.3K | ✓ |
| 7 | Hypoxia — a key regulatory factor in tumour growth | 2002 | Nature reviews. Cancer | 5.1K | ✕ |
| 8 | The Protein Kinase Family: Conserved Features and Deduced Phyl... | 1988 | Science | 5.1K | ✕ |
| 9 | The retinoblastoma protein and cell cycle control | 1995 | Cell | 4.9K | ✓ |
| 10 | Dystrophin: The protein product of the duchenne muscular dystr... | 1987 | Cell | 4.6K | ✕ |
Frequently Asked Questions
What is the role of ubiquitin in protein degradation?
Ubiquitin is a small conserved protein covalently ligated to target proteins by E1, E2, and E3 enzymes, marking them for proteasomal degradation. Hershko and Ciechanover (1998) in "THE UBIQUITIN SYSTEM" explain that this system selectively degrades short-lived regulatory proteins in eukaryotic cells. The process involves polyubiquitin chain formation recognized by the 26S proteasome.
How do E3 ubiquitin ligases function in the pathway?
E3 ubiquitin ligases confer specificity by recognizing target proteins and facilitating ubiquitin transfer from E2 enzymes. The description highlights their regulation as a core focus of the ubiquitin-proteasome proteolytic pathway. This selectivity ensures precise control over protein turnover.
What are deubiquitinating enzymes?
Deubiquitinating enzymes remove ubiquitin from proteins, counterbalancing ubiquitination to regulate degradation or signaling. They play key roles in editing polyubiquitin chains and recycling ubiquitin. The field explores their impact on pathway dynamics.
How is the proteasome involved in cancer therapy?
Proteasome inhibitors block protein degradation, leading to accumulation of pro-apoptotic factors in cancer cells. This approach targets the ubiquitin-proteasome pathway dysregulated in tumors. Developments focus on inhibitors for clinical use in oncology.
What is the connection to NF-κB activation?
The ubiquitin-proteasome pathway processes IκB for degradation, freeing NF-κB for nuclear translocation and gene activation. Ubiquitination of regulatory components drives this inflammatory response. Studies examine its role in immune disorders.
How does SUMOylation interact with ubiquitination?
SUMOylation modifies proteins and influences ubiquitin-proteasome activity by altering ligase function or target recognition. It provides crosstalk between conjugation pathways. Research investigates its regulatory effects on degradation.
Open Research Questions
- ? How do specific E3 ubiquitin ligases achieve substrate specificity under varying cellular conditions?
- ? What mechanisms allow deubiquitinating enzymes to distinguish between degradative and signaling polyubiquitin chains?
- ? In what ways does SUMOylation crosstalk precisely modulate proteasome targeting in stress responses?
- ? How can proteasome inhibitors be optimized to selectively target cancer cells without affecting normal proteostasis?
- ? What are the exact steps linking ubiquitin-mediated IκB degradation to fine-tuned NF-κB activation kinetics?
Recent Trends
The ubiquitin and proteasome pathways field includes 76,032 papers, with sustained focus on E3 ubiquitin ligase regulation, deubiquitinating enzyme functions, SUMOylation modulation, and proteasome inhibitors for cancer therapy as per the topic description.
No growth rate data over 5 years is available.
Citation leaders remain Hershko and Ciechanover's "THE UBIQUITIN SYSTEM" (1998, 8669 citations) and Levine's "p53, the Cellular Gatekeeper for Growth and Division" (1997, 7663 citations), indicating persistent foundational influence.
Research Ubiquitin and proteasome pathways with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Ubiquitin and proteasome pathways with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers